AGLE Aeglea BioTherapeutics, Inc.

4.43
-0.32  -7%
Previous Close 4.75
Open 4.71
Price To book 1.12
Market Cap 59.59M
Shares 13,452,000
Volume 45,925
Short Ratio 0.34
Av. Daily Volume 61,356

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102
Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)
Phase 1 top-line data presented March 23, 2017.
AEB1102
Arginase I deficiency

Latest News

  1. Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer
  2. Achaogen's Plazomicin Gets Breakthrough Therapy Designation
  3. Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update
  4. Aeglea BioTherapeutics to Present at the UBS 2017 Global Healthcare Conference
  5. ETFs with exposure to Aeglea Biotherapeutics, Inc. : May 11, 2017
  6. Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  7. Aeglea reports 1Q loss
  8. Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results
  9. ETFs with exposure to Aeglea Biotherapeutics, Inc. : April 28, 2017
  10. New Strong Buy Stocks for April 13th
  11. Edited Transcript of AGLE earnings conference call or presentation 23-Mar-17 8:30pm GMT
  12. Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
  13. Aeglea BioTherapeutics to Present at the 16th Annual Needham Healthcare Conference
  14. Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 27, 2017
  15. Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
  16. Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting
  17. Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23
  18. Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism
  19. Aeglea Biotherapeutics (AGLE) Looks Good: Stock Jumps 7%